Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
PRAMICONAZOLE
ID: ALA175633
Max Phase: Phase
Molecular Formula: C35H39F2N7O4
Molecular Weight: 659.74
Molecule Type: Small molecule
Associated Items:
ID: ALA175633
Max Phase: Phase
Molecular Formula: C35H39F2N7O4
Molecular Weight: 659.74
Molecule Type: Small molecule
Associated Items:
Synonyms (2): R-126638 | R126638
Synonyms from Alternative Forms(2):
Canonical SMILES: CC(C)N1CCN(c2ccc(N3CCN(c4ccc(OC[C@H]5OC[C@](Cn6cncn6)(c6ccc(F)cc6F)O5)cc4)CC3)cc2)C1=O
Standard InChI: InChI=1S/C35H39F2N7O4/c1-25(2)43-17-18-44(34(43)45)29-6-4-27(5-7-29)40-13-15-41(16-14-40)28-8-10-30(11-9-28)46-20-33-47-22-35(48-33,21-42-24-38-23-39-42)31-12-3-26(36)19-32(31)37/h3-12,19,23-25,33H,13-18,20-22H2,1-2H3/t33-,35+/m0/s1
Standard InChI Key: AEKNYBWUEYNWMJ-QWOOXDRHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: Yes | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 659.74 | Molecular Weight (Monoisotopic): 659.3032 | AlogP: 4.88 | #Rotatable Bonds: 10 |
Polar Surface Area: 88.43 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 3.93 | CX LogP: 5.08 | CX LogD: 5.08 |
Aromatic Rings: 4 | Heavy Atoms: 48 | QED Weighted: 0.24 | Np Likeness Score: -0.89 |
1. Meerpoel L, Backx LJ, Van der Veken LJ, Heeres J, Corens D, De Groot A, Odds FC, Van Gerven F, Woestenborghs FA, Van Breda A, Oris M, van Dorsselaer P, Willemsens GH, Vermuyten KJ, Marichal PJ, Vanden Bossche HF, Ausma J, Borgers M.. (2005) Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology., 48 (6): [PMID:15771461] [10.1021/jm0494772] |
2. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
3. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
4. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
Source(3):